Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| GALT | Galectin Therapeutics | $4.04 | -$2.12 | -34.42% | 2.4M | $397M | $0.73$7.13 |
| PULM | Pulmatrix | $2.45 | -$1.27 | -34.14% | 123.9K | $14M | $2.32$10.40 |
| RKLZ | Tidal Trust II - Defiance Daily Target 2x Short Rklb ETF | $5.97 | -$2.31 | -27.89% | 2.3M | - | $5.91$25.51 |
| SAVA | Cassava Sciences | $2.16 | -$0.70 | -24.39% | 2.8M | $138M | $1.15$4.98 |
| ALT | Altimmune | $4.00 | -$1.06 | -20.89% | 317.6K | $527M | $2.90$8.75 |
| IRON | Disc Medicine | $75.19 | -$15.25 | -16.86% | 1.4M | $3.4B | $30.82$99.50 |
| FCUV | Focus Universal | $2.43 | -$0.49 | -16.67% | 85.7K | $24M | $1.80$10.90 |
| AFJK | Aimei Health Technology | $44.00 | -$8.23 | -15.76% | 70.9K | $320M | $6.75$98.15 |
| NVA | Nova Minerals | $7.00 | -$1.14 | -14.01% | 1.5M | $282M | $1.68$16.28 |
| SKIL | Skillsoft | $7.48 | -$1.21 | -13.92% | 159.6K | $76M | $4.65$34.43 |
Related Articles
Featured Article
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Adam Spatacco|Aug 9, 2024
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
Alex Carchidi|Jul 20, 2024
At least one of the pair has a credible shot at finding a home in the market.
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
Alex Carchidi|Jul 10, 2024
Both competitors have promising lead programs, and enough cash, too.
Advertisement
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
Alex Carchidi|Jun 30, 2024
While their share prices have traveled different paths recently, the similarity between the two companies is striking.
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
Alex Carchidi|Jun 29, 2024
The market for weight loss medicines keeps getting hotter and hotter.
Is There Any Hope for Cassava Sciences Stock?
Alex Carchidi|Feb 3, 2024
Battered by controversy, this company will need to show real results to prosper.
1 Big Red Flag to Fear When a Stock Is Down
Alex Carchidi|Oct 31, 2023
Playing the blame game does not make for an effective turnaround strategy.
Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.
Keith Speights|Mar 22, 2023
It's not the end of the story for this once high-flying biotech stock.
3 Big Reasons to Sell Cassava Sciences Stock Right Now
Alex Carchidi|Feb 1, 2023
It isn't about running out of money, but it's still laden with risk.
My 3 Top Biotech Stock Picks for 2023
George Budwell, PhD|Nov 22, 2022
Biotech stocks are set to shine in 2023.
